Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Single-dose, Parallel Controlled Phase I Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Envafolimab in Healthy Male Subjects Before and After the Manufacturing Process Change

Next Previous
Trial Profile

A Randomized, Double-blind, Single-dose, Parallel Controlled Phase I Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Envafolimab in Healthy Male Subjects Before and After the Manufacturing Process Change

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Envafolimab (Primary)
  • Indications Biliary cancer; Endometrial cancer; Gastrointestinal cancer; Hepatitis B; HER2 positive breast cancer; HIV infections; Liver cancer; Malignant fibrous histiocytoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors 3D Medicines

Most Recent Events

  • 12 Aug 2024 Status changed from recruiting to completed.
  • 30 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.
  • 12 Jul 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top